SCHEMBL3212943

SCHEMBL3212943

COCCOc1ccc(CCCO)c(OCC2CC2)c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR2 P34972 3/20 0.44
CNR1 P21554 2/20 0.44
MEN1 O00255 1/20 0.39
ALDH1A1 P00352 1/20 0.39
KMT2A Q03164 1/20 0.39
PARP15 Q460N3 1/20 0.38
PARP10 Q53GL7 1/20 0.38
TSHR P16473 1/20 0.38
FFAR1 O14842 1/20 0.37
PDE4A P27815 5/20 0.37
PDE4D Q08499 5/20 0.37
PDE4B Q07343 2/20 0.36
PDE4C Q08493 2/20 0.36
RIPK1 Q13546 1/20 0.36
MAOB P27338 2/20 0.36
PPARG P37231 2/20 0.35
PDE3B Q13370 2/20 0.35
PDE3A Q14432 2/20 0.35
ALB P02768 1/20 0.34
ACHE P22303 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3217506 0.85 CNR1 (0.39) CNR2CNR1PARP15PARP10FFAR1
SCHEMBL3219692 0.83 RAB9A (0.41) TSHRFFAR1
SCHEMBL4602988 0.83 FFAR1 (0.53) CNR2CNR1PARP15PARP10TSHR
SCHEMBL3213102 0.81 CNR1 (0.38) CNR2CNR1MEN1ALDH1A1KMT2A
SCHEMBL3202817 0.80 CNR2 (0.44) CNR2CNR1MEN1ALDH1A1KMT2A
SCHEMBL3217103 0.78 LTA4H (0.50) MEN1KMT2A
SCHEMBL27716279 0.76 PPARG (0.44) CNR2CNR1MEN1ALDH1A1KMT2A
SCHEMBL4602019 0.76 PPARG (0.45) CNR2CNR1MEN1ALDH1A1KMT2A
SCHEMBL12924070 0.76 TSHR (0.56) CNR2CNR1MEN1ALDH1A1KMT2A
SCHEMBL5110087 0.75 NPSR1 (0.46) MEN1ALDH1A1KMT2APPARG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100041892-A1 Therapeutic agent for diabetes ABE HIDENORI 2010-02-18 US disclosed
US-20090270631-A1 Therapeutic agent for diabetes ABE HIDENORI 2009-10-29 US disclosed
EP-1912645-A2 THERAPEUTIC AGENT FOR DIABETES Takeda Pharmaceutical Company Limited (JP) 2008-04-23 EP disclosed
US-20080009530-A1 Therapeutic Agent for Diabetes TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-01-10 US disclosed
WO-2007018314-A2 THERAPEUTIC AGENT FOR DIABETES TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2007-02-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090270631-A1 Therapeutic agent for diabetes FABP4, SLC5A1, SLC5A2 CNR2 3597/4885CNR1 3006/4885MEN1 3927/4885
US-20080009530-A1 Therapeutic Agent for Diabetes FABP4, SLC5A1, SLC5A2 CNR2 3254/4885CNR1 2517/4885MEN1 3517/4885
US-20100041892-A1 Therapeutic agent for diabetes FABP4, SLC5A1, SLC5A2 CNR2 3597/4885CNR1 3006/4885MEN1 3927/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.